Table 1 Correlations between EIF5A2 expression and clinicopathologic characteristics of EOC patients
From: EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis
Characteristics | All cases | EIF5A2 protein | P value | |
|---|---|---|---|---|
Low expression | High expression | |||
Age (years, mean) | 76 | 57 | 55 | 0.28 |
Histological type | Â | Â | Â | 0.201 |
 Serous | 61 | 25 (41.0%) | 36 (59.0%) |  |
 Others | 15 | 9 (60.0%) | 6 (40.0%) |  |
Histological grade | Â | Â | Â | 0.724 |
 Well/moderate | 10 | 5 (50.0%) | 5 (50.0%) |  |
 Poorly | 66 | 29 (43.9%) | 37 (56.1%) |  |
Lymphatic metastasis | Â | Â | Â | 0.108 |
 No | 63 | 30 (47.6%) | 33 (52.4%) |  |
 Yes | 13 | 4 (30.8%) | 9 (69.2%) |  |
FIGO stage | Â | Â | Â | 0.263 |
 IIIc | 58 | 28 (48.3%) | 30 (51.7%) |  |
 IV | 18 | 6 (33.3%) | 12 (66.7%) |  |
Residual disease | Â | Â | Â | 0.381 |
 ≤ 10 mm | 59 | 28 (47.5%) | 31 (52.5%) |  |
 > 10 mm | 17 | 6 (35.3%) | 11 (64.7%) |  |
Clinical response | Â | Â | Â | 0.039 |
 Complete | 68 | 33 (48.5%) | 35 (51.5%) |  |
 Partial | 7 | 1 (14.3%) | 6 (85.7%) |  |
 Non-response | 1 | 0 (0.0%) | 1 (100.0%) |  |
Platinum sensitivity | Â | Â | Â | 0.014 |
 Sensitive | 60 | 31 (51.7%) | 29 (48.3%) |  |
 Resistant* | 16 | 3 (18.8%) | 13 (81.2%) |  |